Xu Chen, Ming Huang, Jianmin Fang, Jian Huang, Tianxin Lin. "Intravesical disitamab vedotin (RC48) for patients with HER2-expressing high-risk non-muscle-invasive bladder cancer: A dose-escalation phase I trial.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.16_suppl.4605